Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.

This article aims to review our current understanding of risankizumab through the analysis of the various clinical trials.
PMID: 32510689 [PubMed - in process]

Source: Skin Therapy Letter - April 30, 2020 Category: Dermatology Authors: McDonald J, Maliyar K, Gooderham MJ Tags: Skin Therapy Lett Source Type: research